Literature DB >> 8733946

Analysis of animal pharmacokinetic data: performance of the one point per animal design.

E I Ette1, A W Kelman, C A Howie, B Whiting.   

Abstract

A simulation study was carried out to determine the impact of various design factors on the accuracy and precision with which population pharmacokinetic parameters are estimated in preclinical pharmacokinetic studies. A drug given by intravenous bolus injection and having mono-exponential disposition characteristics was assumed. The factors investigated were (i) number of animals sampled at specified times with one observation taken per animal, (ii) error in observed concentration measurements, and (iii) doubling the number of observations per animal while varying the number of animals. Data were analyzed with the NONMEM program, and the least number of animals per time point (where each animal supplied one concentration-time point) required for accurate and precise parameter estimation was determined. The one observation per animal design yielded biased and imprecise estimates of variability, and residual variability could not be estimated. Increasing the error in the concentration measurement led to a significant deterioration in the accuracy and precision with which variability was estimated. Obtaining a second sample from each animal practically eliminated bias and facilitated the partitioning of interanimal variability and residual intraanimal variability, by introducing information about the latter. Doubling the total number of observations per animal required using half (i.e., 50) the total number of animals required for accurate and precise parameter estimation with the one sample per animal design.

Mesh:

Year:  1995        PMID: 8733946     DOI: 10.1007/bf02353461

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  9 in total

1.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

2.  The fate of FD&C Red No. 2 and its metabolite, naphthionic acid, after different routes of administration in the rat.

Authors:  A B Pritchard; P A Holmes; J C Kirschman
Journal:  Toxicol Appl Pharmacol       Date:  1976-01       Impact factor: 4.219

3.  The influence of assay variability on pharmacokinetic parameter estimation.

Authors:  D A Graves; C S Locke; K T Muir; R P Miller
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

4.  Distribution and excretion of the mercury chelating agent sodium 2,3-dimercaptopropane-1-sulfonate in the rat.

Authors:  B Gabard
Journal:  Arch Toxicol       Date:  1978-02-14       Impact factor: 5.153

5.  Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.

Authors:  E I Ette; A W Kelman; C A Howie; B Whiting
Journal:  Ann Pharmacother       Date:  1993-09       Impact factor: 3.154

Review 6.  Methods for obtaining drug time course data from individual small laboratory animals: serial microblood sampling and assay.

Authors:  B H Migdalof
Journal:  Drug Metab Rev       Date:  1976       Impact factor: 4.518

7.  Problems and pitfalls in estimating average pharmacokinetic parameters.

Authors:  E Martin; W Moll; P Schmid; L Dettli
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Pharmacokinetics of sodium valproate in dog and mouse.

Authors:  W Löscher; H Esenwein
Journal:  Arzneimittelforschung       Date:  1978

9.  Interspecies comparison of acivicin pharmacokinetics.

Authors:  J P McGovren; M G Williams; J C Stewart
Journal:  Drug Metab Dispos       Date:  1988 Jan-Feb       Impact factor: 3.922

  9 in total
  19 in total

1.  Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  Designing population pharmacokinetic studies: performance of mixed designs.

Authors:  E O Fadiran; C D Jones; E I Ette
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

3.  Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

4.  Design and power of a population pharmacokinetic study.

Authors:  P I Lee
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

Review 5.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 7.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

8.  Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin) in CD1 mice following intravenous and intraperitoneal injection.

Authors:  G W Boswell; D R Miles; P A Thiemann; M Mesfin
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

9.  Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach.

Authors:  Monica Rodriguez; M Angeles Carlos; Ignacio Ortega; Elena Suarez; Rosario Calvo; John C Lukas
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

10.  Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.

Authors:  Ehab S EL Desoky; Eliane Fuseau; Salah EL Din Amry; Valérie Cosson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.